Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

138 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-06

Study Completion Date

2017-03-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to investigate the relationship between sleep quality, quality of life,other disorders and therapies in Multiple Sclerosis (MS) patients treated with Betaferon.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Depression and Fatigue in MS Patients Treated With Betaferon.

NCT01354665

Multiple Sclerosis

COMPLETED

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00206635

Multiple Sclerosis

COMPLETED

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study

NCT03134573

Multiple Sclerosis

COMPLETED

Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

NCT00963833

Multiple Sclerosis

COMPLETED

Betaferon Use in Children and Adolescents With Multiple Sclerosis

NCT03577977

Multiple Sclerosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Interferon beta-1b (Betaferon, BAY 86-5046)

Intervention Type DRUG

Patients will be followed-up for 24 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interferon beta-1b (Betaferon, BAY 86-5046)

Patients will be followed-up for 24 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ≥ 18 years of age with relapsing remitting multiple sclerosis or a clinically isolated syndrome and an expanded disability status scale score ≤5.
* Patients must be on treatment with Betaferon and tolerate Betaferon according to the investigator's evaluation, but should not have received Betaferon longer than six months.
* Written informed consent must be obtained

Exclusion Criteria

* Patients who do not tolerate Betaferon according to the investigator's evaluation or have been treated with Betaferon for more than six months.
* Patients receiving any other disease modifying drug or MS specific treatments
* Contraindications of Betaferon described in the Summary of Product Characteristics.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No